Concepedia

Peter M. Voorhees

PM

4

Publications

155

Citations

4

H-Index

2013

Active since

Affiliations

Levine Cancer Institute(Current)

UNC Lineberger Comprehensive Cancer Center

University of North Carolina at Chapel Hill

Harvard University

Erasmus MC Cancer Institute

Peter M. Voorhees is an author at Levine Cancer Institute specializing in radiation oncology, hematology, and health sciences.

ORCID

Top concepts

Publications per year

2013–2022

4

Publications

4

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study

Paul G. Richardson, Sara Bringhen, Peter M. Voorhees et al. · The Lancet Haematology · 2020 · 86 citations

, , +6

Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies

Nishitha Reddy, Peter M. Voorhees, Brett E. Houk et al. · Clinical Lymphoma Myeloma & Leukemia · 2013 · 40 citations

, , +11

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Yaël C. Cohen, Philippe Moreau, Jaszianne Tolbert et al. · Blood · 2022 · 16 citations

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1

Sara Bringhen, Peter M. Voorhees, Torben Plesner et al. · British Journal of Haematology · 2021 · 13 citations · Full text

, , +16

Rows per page

1–4 of 4